Equity Issuances

Blue Owl Credit Income Corp. issued 2,872,794 of common stock to feeder vehicles primarily created to hold the Company’s Class I shares for $26,831,893.

“As of January 2, 2026, Blue Owl Credit Income Corp. (the “ Company ,” “ we ” or “ us ”) sold unregistered shares of its Class I common stock to feeder vehicles primarily created to hold the Company’s Class I shares. The offer and sale of these Class I shares was exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) and/or Regulation S thereunder (the “ Private Offering ”). The following table details the shares sold: Date of Unregistered Sale Approximate Number of Shares of Class I Common Stock Consideration As of January 2, 2026 (number of shares finalized on January 26, 2026) 2,872,794 $ 26,831,893”

Cingulate Inc. issued warrants to purchase 1,868,482 shares of Common Stock of warrant to the several purchasers named therein, including certain officers, directors and other affiliates of the Company for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).

“On January 27, 2026, Cingulate Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with the several purchasers named therein (the " Purchasers "), including certain officers, directors and other affiliates of the Company, for the private placement (the " Private Placement ") of: (i) 2,147,471 shares of the Company’s common stock, par value $0.0001 per share (the " Common Stock "), (ii) 973 shares of Series A convertible preferred stock (the " Preferred Stock ") with a stated value of $1,000 and a conversion price equal to a $5.04 per share of Common Stock and (iii) warrants to purchase 1,868,482 shares of Common Stock (the " Warrant Shares ") for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).”

Cingulate Inc. issued 973 shares of Series A convertible preferred stock of preferred stock to the several purchasers named therein, including certain officers, directors and other affiliates of the Company for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).

“On January 27, 2026, Cingulate Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with the several purchasers named therein (the " Purchasers "), including certain officers, directors and other affiliates of the Company, for the private placement (the " Private Placement ") of: (i) 2,147,471 shares of the Company’s common stock, par value $0.0001 per share (the " Common Stock "), (ii) 973 shares of Series A convertible preferred stock (the " Preferred Stock ") with a stated value of $1,000 and a conversion price equal to a $5.04 per share of Common Stock and (iii) warrants to purchase 1,868,482 shares of Common Stock (the " Warrant Shares ") for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).”

Cingulate Inc. issued 2,147,471 shares of the Company’s common stock of common stock to the several purchasers named therein, including certain officers, directors and other affiliates of the Company for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).

“On January 27, 2026, Cingulate Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with the several purchasers named therein (the " Purchasers "), including certain officers, directors and other affiliates of the Company, for the private placement (the " Private Placement ") of: (i) 2,147,471 shares of the Company’s common stock, par value $0.0001 per share (the " Common Stock "), (ii) 973 shares of Series A convertible preferred stock (the " Preferred Stock ") with a stated value of $1,000 and a conversion price equal to a $5.04 per share of Common Stock and (iii) warrants to purchase 1,868,482 shares of Common Stock (the " Warrant Shares ") for aggregate gross proceeds of approximately $12,000,000, at a price per share of $5.14 per share of Common Stock (including $0.10 per Warrant Share).”

Blue Owl Technology Income Corp. issued 718,634 of common stock to feeder vehicles primarily created to hold the Company's Class I shares for $7,459,423.

“Date of Unregistered Sale Approximate Number of Shares of Class I Common Stock Consideration As of January 2, 2026 (number of shares finalized on January 26, 2026) 718,634 $ 7,459,423”

Strive, Inc. issued 1,320,000 shares of preferred stock to institutional investors for public offering price of $90 per share, total $225 million.

“Strive, Inc. (Nasdaq: ASST; SATA) ("Strive" or the "Company") today announced the closing of its follow-on offering (the "offering") of 1,320,000 shares of Strive’s Variable Rate Series A Perpetual Preferred Stock (the "SATA Stock"), at a public offering price of $90 per share.”

Strive, Inc. issued approximately 930,000 newly issued shares of preferred stock to holders of Semler Convertible Notes for exchange of $90 million aggregate principal amount of Semler Convertible Notes.

“On January 22, 2026, Strive, Inc. ("Strive" or the "Company") entered into privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of the outstanding 4.250% Convertible Senior Notes due 2030 (the "Semler Convertible Notes") issued by Semler Scientific, Inc., a wholly-owned subsidiary of the Company ("Semler Scientific") , and guaranteed by the Company, pursuant to an indenture, dated as of January 28, 2025, between Semler Scientific and U.S Bank Trust Company, National Association, as trustee (the "Trustee"), as amended by a supplemental indenture, dated January 16, 2026, by and among Semler Scientific, the Company and the Trustee, representing $90 million aggregate principal amount of the Semler Convertible Notes (the "Exchange Notes"), pursuant to which such holders exchanged their Semler Convertible Notes for approximately 930,000 newly issued shares of the Company’s Variable Rate Series A Perpetual Preferred Stock, $0.001 par value per share (the "”

HPS Corporate Capital Solutions Fund issued 211,127 Class I Common Shares and 523,919 Class D Common Shares of common stock to accredited investors or non-U.S. persons for $5.72 million and $14.18 million, respectively.

“On January 1, 2026, HPS Corporate Capital Solutions Fund (the “ Fund ”) sold common shares of beneficial interest (the “ Shares ”). The purchase price per share and number of Shares issued was finalized on January 27, 2026. The purchase price per share was equal to $27.07. The following table details the Shares sold on January 1, 2026: Common Shares Issued Total Consideration (in millions) Class I Common Shares 211,127 $ 5.72 Class D Common Shares 523,919 $ 14.18”

Lord Abbett Private Credit Fund issued approximately 3,562,500 Common Shares of common stock to accredited investors for aggregate offering price of approximately $89.5 million, reflecting a purchase price of $25.12 per Common Share.

“As of January 1, 2026, Lord Abbett Private Credit Fund (“we”, the “Company” or the “Fund”) issued and sold approximately 3,562,500 of the Company’s common shares of beneficial interest (the “Common Shares”) for an aggregate offering price of approximately $89.5 million, reflecting a purchase price of $25.12 per Common Share (with the final number of Common Shares being determined on January 23, 2026).”

Lord Abbett Private Credit Fund S issued approximately 502,788 of the Company's common shares of beneficial interest of common stock for approximately $12.6 million, reflecting a purchase price of $25.11 per Common Share.

“As of January 1, 2026, Lord Abbett Private Credit Fund S (“we”, the “Company” or the “Fund”), issued and sold approximately 502,788 of the Company’s common shares of beneficial interest (the “Common Shares”) for an aggregate offering price of approximately $12.6 million, reflecting a purchase price of $25.11 per Common Share (with the final number of Common Shares being determined on January 23, 2026).”

VistaOne, L.P. issued 401,579 Class A-B Units and 1,354,968 Class A-I Units of unit to third-party investors including through VistaOne (TE), L.P. for aggregate consideration of approximately $54.5 million.

“As of January 1, 2026, VistaOne, L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) for aggregate consideration of approximately $54.5 million.”

Carlyle Private Equity Partners Fund, L.P. issued 278,119 Class E-I Units and 17,813 Class C Units of unit to certain investors for $8,200,000.

“On January 2, 2026, Carlyle Private Equity Partners, L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) to certain investors for aggregate consideration of approximately $8.2 million.”

Enveric Biosciences, Inc. issued up to 23,016 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (Placement Agent) for exercise price equal to $5.5125 per share.

“Agent Warrants”) to purchase up to 23,016 shares of Common Stock to the Placement Agent (including its designees). The Placement Agent Warrants have an exercise price equal to $5.5125 per share and are exercisable for five (5) years from the commencement of sales in the Offerings. The Common Warrants and Placement Agent Warrants and the shares of our Common”

Enveric Biosciences, Inc. issued up to 328,802 shares of Common Stock of warrant to certain institutional investors for exercise price of $4.16 per share.

“up to 328,802 shares of Common Stock (the “Series H Warrants”, and collectively with the Series G Warrants, the “Common Warrants”). The Common Warrants have an exercise price of $4.16 per share (subject to customary adjustments as set forth in the Common Warrants) and are exercisable immediately. The Series G Warrants will expire five (5) following the”

Enveric Biosciences, Inc. issued 328,802 shares of common stock to certain institutional investors for $4.41 per share.

“the Company agreed to issue and sell to the Investors in a registered direct offering, an aggregate of 328,802 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price of $4.41 per share”

INOVIO PHARMACEUTICALS, INC. issued up to 13,564,268 shares of warrant for exercise price of $1.75 per share.

“each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof), and have an exercise price of $1.75 per share (or $1.749 per Pre-Funded Warrant) and would otherwise have expired at 5:00 p.m. New York City time on January 28, 2026, which is 30 days following the Company’s public”

INTERNATIONAL TOWER HILL MINES LTD issued 1,501,982 Common Shares of common stock to Paulson & Co. Inc. for $2.22 per share.

“agreed to issue and sell an aggregate of 29,280,000 of its common shares, no par value (the “ Common Shares ”) to the Underwriters (the “ Offering ”) at a price to the public of $2.22 per Common Share (the “ Offering Price ”). Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option to purchase, for a period of 30 days from”

INTERNATIONAL TOWER HILL MINES LTD issued 18,018,018 Common Shares of common stock to Paulson & Co. Inc. for $2.22 per share.

“On January 27, 2026 (the “ Closing Date ”), substantially concurrently with the closing of the Offering, the Company issued and sold to Paulson 18,018,018 Common Shares (the “ Paulson Shares ”), no par value, of the Company, at the price per Share of $2.22, for aggregate proceeds to the Company of approximately $40 million”

Vivani Medical, Inc. issued 1,351,351 shares of common stock of common stock to entity affiliated with Gregg Williams, Chairman of the Company’s board of directors for purchase price of $1.48 per share, gross proceeds of approximately $2.0 million.

“Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated January 25 , 2026 (the “Purchase Agreement”), with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) for the purchase of an aggregate of 1,351,351 shares of common stock, par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $1. 4 8 per share (the “Private Placement Shares”), the last reported sale price of the Common Stock on January 2 3 , 2026 . This private placement of Common Stock resulted in gross proceeds of approximately $ 2.0 million to the Company.”

AI Era Corp. issued convertible note to Boot Capital LLC for principal amount of $50,000.00.

“the Company issued a Note in the principal amount of $50,000.00 for a purchase price of $50,000.00 (with no original issue discount).”

AI Era Corp. issued convertible note to Vanquish Funding Group Inc. for principal amount of $57,000.00.

“the Company issued a Note in the principal amount of $57,000.00 for a purchase price of $57,000.00 (with no original issue discount).”

Cottonwood Communities, Inc. issued 147,939 shares of Series A Convertible Preferred Stock of preferred stock to accredited investors for aggregate proceeds of $1,453,700.

“Sales of Series A Convertible Stock During the period from January 16, 2026 through January 26, 2026, we issued and sold 147,939 shares of Series A Convertible Preferred Stock in the Series A Convertible Private Offering and received aggregate proceeds of $1,453,700.”

Zeo Energy Corp. issued up to $30.0 million in aggregate gross purchase price of newly issued Class A Common Stock; initial issuance of shares with an aggregate value of $100,000 (the of common stock to White Lion Capital, LLC for purchase price per share based on market prices at time of notice.

“The Company has the right, but not the obligation, to require White Lion to purchase, from time to time as determined by the Company, up to $30.0 million in aggregate gross purchase price of newly issued Class A Common Stock of the Company (the "Common Stock").”

KKR Infrastructure Conglomerate LLC issued Class I Shares: 4,234,422; Class S Shares: 4,108,437; Class D Shares: 202,216 of common stock to accredited investors and non-U.S. investors for aggregate consideration of $256,029,732.

“Class Number of Shares Sold (1) Aggregate Consideration (1) Class I Shares 4,234,422 $ 126,859,046 Class S Shares 4,108,437 123,116,286 Class D Shares 202,216 6,054,400 Total $ 256,029,732 (1) Share and dollar amounts are rounded to the nearest whole number. The offer and sale of the Investor Shares were exempt from the registration provisions of the Securities”

Mag Magna Corp issued one (1) share of its Series X Preferred Stock of preferred stock to Harpreet Sangha.

“In January 2026, the Company issued one (1) share of its Series X Preferred Stock (the “Series X Share” ) to Harpreet Sangha, its sole officer and director and holder of the majority voting power.”

North Haven Private Income Fund A LLC issued approximately 174,540 of the Company's Class I units of unit to accredited investors for aggregate offering price of approximately $3.5 million, reflecting a purchase price of $20.14 per unit.

“sold approximately 174,540 of the Company’s Class I units (the “Units”) for an aggregate offering price of approximately $3.5 million, reflecting a purchase price of $20.14 per unit”

LGAM Private Credit LLC issued approximately 773,332 of the Company’s Common Units of common stock to accredited investors for $19.93 per unit.

“sold approximately 773,332 of the Company’s Common Units (the “Units”) for an aggregate offering price of approximately $15.4 million, reflecting a purchase price of $19.93 per unit (with the final number of Units being determined on January 26, 2026)”

Fortress Private Lending Fund issued 4,928,630 of common stock to accredited investors for aggregate consideration of $121.5 million.

“the “Company”) sold its Class I common shares of beneficial interest, par value $0.01 per share (the “Shares”) for aggregate consideration of $121.5 million. The number of Shares to be issued was finalized on January 21, 2026. The purchase price per Share equaled the Company’s net asset value (“NAV”) per Share as of December 31, 2025”

TPG Private Equity Opportunities, L.P. issued 1,480,251 Class R-I Units; 1,189,720 Class R-S Units; 263,187 Class F Units of unit to third-party investors for aggregate consideration of $90.3 million.

“On January 1, 2026, TPG Private Equity Opportunities, L.P., a Delaware limited partnership (the “Fund” or “T-POP”), sold unregistered limited partnership units (the “Units”) of the Fund as part of its continuous private offering for aggregate consideration of $90.3 million.”

Blue Water Acquisition Corp. III issued up to 50,000 New Units of unit to Yorkville BW Acquisition Sponsor, LLC for $500,000.00 aggregate principal amount of convertible unsecured promissory note.

“On January 26, 2026, Blue Water Acquisition Corp. III (the “Company”) issued a convertible unsecured promissory note (the “Working Capital Note”) in the aggregate principal amount of $500,000.00 to Yorkville BW Acquisition Sponsor, LLC, a Florida limited liability company (the “Sponsor”), in order to provide the Company with additional working capital.”

Archimedes Tech SPAC Partners III Co. issued 762,000 units of unit to the Sponsor and BTIG for $10.00 per Private Unit, generating total proceeds of $7,620,000.

“Simultaneously with the closing of the IPO, the Company consummated a private placement (the “Private Placement”) of an aggregate of 762,000 units (the “Private Units”) to the Sponsor and BTIG, at a price of $10.00 per Private Unit, generating total proceeds of $7,620,000.”

Aldabra 4 Liquidity Opportunity Vehicle, Inc. issued 3,126,666 warrants to the Sponsor and an aggregate of 1,740,000 warrants to the underwriters of warrant to the Sponsor and the underwriters for $1.50 per Private Placement Warrant.

“On January 23, 2026, simultaneously with the consummation of the Offering, the Company consummated the private placement of 3,126,666 warrants to the Sponsor and an aggregate of 1,740,000 warrants to the underwriters (collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant, generating gross proceeds of $7,300,000 (the “Private Placement”).”

PennantPark Private Income Fund issued 559,375 of the Company’s common shares of common stock to accredited investors for aggregate consideration of approximately $14,141,000.

“On January 2, 2026, PennantPark Private Income Fund (the “Company”) issued and sold 559,375 of the Company’s common shares of beneficial interest, par value $0.001 per share (the “Common Shares”) (with the final number of Common Shares issued being determined on January 21, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $14,141,000.”

Praetorian Acquisition Corp. issued 165,000 Class A Ordinary Shares of common stock to Clear Street LLC (representative of the underwriters) for Issued in private placement upon consummation of the Offering; no separate consideration mentioned.

“The Company also issued in a private placement to the Underwriters 165,000 Class A Ordinary Shares upon the consummation of the Offering (the “ Representative Shares ”).”

Praetorian Acquisition Corp. issued 4,670,000 warrants of warrant to Praetorian Sponsor LLC for $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $4,670,000.

“Simultaneously with the closing of the Offering, pursuant to the Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 4,670,000 warrants (the “ Private Placement Warrants ”) to the Sponsor at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $4,670,000.”

Helix Acquisition Corp. III issued 497,500 Class A Ordinary Shares of common stock to Helix Holdings III LLC (the Sponsor) for $10.00 per Private Placement Share.

“Simultaneously with the closing of the IPO, pursuant to the Private Placement Shares Purchase Agreement, the Company completed the private sale of 497,500 Class A Ordinary Shares (the “ Private Placement Shares ”) at a purchase price of $10.00 per Private Placement Share, to the Sponsor, generating gross proceeds to the Company of $4,975,000.”

Nuo Therapeutics, Inc. issued warrant to four lenders (collectively, the 'Lenders').

“On January 23, 2026, the closing date of the Initial Funding, and pursuant to the Loan Agreement, the Company issued to each Lender warrants, some of which are subject to vesting provisions, to purchase shares of the Company’s common stock”

IROBOT CORP issued 10,000 shares of common stock of common stock to the Company’s new stockholder.

“Upon the effectiveness of the Plan on the Effective Date, the Company issued an aggregate of 10,000 shares of common stock, par value $0.001 (the “New Common Stock”), to the Company’s new stockholder in accordance with the terms of the Plan and certain other agreements.”

OLB GROUP, INC. issued up to an aggregate of 2,166,666 shares of Common Stock of warrant to certain institutional investors for combined purchase price per Share and accompanying Warrant of $0.60.

“in a concurrent private placement, warrants (the “Warrants”) to purchase up to an aggregate of 2,166,666 shares of Common Stock (the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”), at a combined purchase price per Share and accompanying Warrant of $0.60”

OLB GROUP, INC. issued 2,166,666 shares of common stock to certain institutional investors for combined purchase price per Share and accompanying Warrant of $0.60.

“of Common Stock (the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”), at a combined purchase price per Share and accompanying Warrant of $0.60 (the “Offering”). The Warrants will be exercisable on the six-month anniversary of issuance, will expire five years following the date of issuance, and have an exercise price of”

FinTrade Sherpa, Inc. issued 227,000,000 shares of common stock to the sellers.

“On January 23, 2026 the Company issued the 227,000,000 shares as noted above. In connection with the asset acquisition described in Item 1.01, the Company issued the shares of its common stock to the sellers.”

Ascent Solar Technologies, Inc. issued Series B Warrants to purchase up to 909,091 shares of warrant to institutional and accredited investors for part of unit with Shares at $5.50 per Share and accompanying Warrants.

“On January 23, 2026, Ascent Solar Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 454,546 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 1,363,636 shares of Common Stock, at an exercise price of $0.0001 per share, (iii) Series A warrants (the “Series A Warrants”) to purchase up to 1,818,182 shares of Common Stock at an exercise price of $5.50 per share, and (iv) Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”) to purchase up to 909,091 shares of Common Stock at an exercise price of $5.50 per share.”

Ascent Solar Technologies, Inc. issued Series A Warrants to purchase up to 1,818,182 shares of warrant to institutional and accredited investors for part of unit with Shares at $5.50 per Share and accompanying Warrants.

“On January 23, 2026, Ascent Solar Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 454,546 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 1,363,636 shares of Common Stock, at an exercise price of $0.0001 per share, (iii) Series A warrants (the “Series A Warrants”) to purchase up to 1,818,182 shares of Common Stock at an exercise price of $5.50 per share, and (iv) Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”) to purchase up to 909,091 shares of Common Stock at an exercise price of $5.50 per share.”

Ascent Solar Technologies, Inc. issued Pre-Funded Warrants to purchase up to 1,363,636 shares of warrant to institutional and accredited investors for $5.4999 per Pre-Funded Warrant.

“On January 23, 2026, Ascent Solar Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 454,546 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 1,363,636 shares of Common Stock, at an exercise price of $0.0001 per share, (iii) Series A warrants (the “Series A Warrants”) to purchase up to 1,818,182 shares of Common Stock at an exercise price of $5.50 per share, and (iv) Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”) to purchase up to 909,091 shares of Common Stock at an exercise price of $5.50 per share.”

Ascent Solar Technologies, Inc. issued 454,546 shares of common stock to institutional and accredited investors for $5.50 per share.

“On January 23, 2026, Ascent Solar Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 454,546 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 1,363,636 shares of Common Stock, at an exercise price of $0.0001 per share, (iii) Series A warrants (the “Series A Warrants”) to purchase up to 1,818,182 shares of Common Stock at an exercise price of $5.50 per share, and (iv) Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”) to purchase up to 909,091 shares of Common Stock at an exercise price of $5.50 per share.”

Orgenesis Inc. issued warrant to purchase 15% of the fully diluted share capital of warrant to Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P for aggregate exercise price equal to $250,000.

“issue to Lender a warrant to purchase 15% of the fully diluted share capital of either the Company or Theracell, at the Lender’s discretion, for an aggregate exercise price of $250,000 and exercisable for three years from issuance with respect to each cumulative drawdown of $1,000,000 under the loan and credit facility referenced above. With respect to the first”

SPLASH BEVERAGE GROUP, INC. issued convertible note to C/M Capital Master Fund, LP for promissory note in lieu of commitment shares under prior ELOC agreement; initial principal amount of $525,000, subject to increase up to $700,000.

“of the ELOC Agreement was previously filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on September 25, 2025. The Note has an initial principal amount of $525,000, which shall be subject to increase up to $700,000 in connection with sales made under the ELOC Agreement which increase, if applicable, would reflect the additional 0.5% of”

4D Molecular Therapeutics, Inc. issued 1,750,000 shares of warrant to Biotechnology Value Fund, L.P. and its affiliates for exchanged 1,750,000 shares of the Company's common stock for a pre-funded warrant.

“BVF exchanged 1,750,000 shares of the Company’s common stock for a pre-funded warrant to acquire 1,750,000 shares of the Company’s common stock”

4D Molecular Therapeutics, Inc. issued 4,850,000 shares of warrant to RA Capital Healthcare Fund, L.P. for exchanged 4,850,000 shares of the Company's common stock for a pre-funded warrant.

“pursuant to which RA Capital exchanged 4,850,000 shares of the Company’s common stock for a pre-funded warrant to acquire 4,850,000 shares of the Company’s common stock”

CoreWeave, Inc. issued 22,935,780 shares of the Company's Class A common stock of common stock to NVIDIA Corporation for aggregate purchase price of $2 billion in cash.

“On January 23, 2026, the Company completed the issuance and sale of 22,935,780 shares of the Company's Class A common stock, par value $0.000005 per share (the "Shares"), pursuant to the Purchase Agreement, at a price of $87.20 per share for an aggregate purchase price of $2 billion in cash.”